Another meta-analysis found that SGLT2 inhibitors had similar risks of hypoglycaemia, urinary tract infection, genital infection, hypovolemia, and fracture compared to placebo in Japanese patients (57). This evidence concerns the gene SLC5A2 and urinary tract infection.